Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Health Policy,Pharmacology
Reference44 articles.
1. June CH, Sadelain M. Chimeric antigen receptor therapy. N Engl J Med. 2018;379(1):64–73.
2. Newick K, O’Brien S, Moon E, Albelda SM. CAR T cell therapy for solid tumors. Annu Rev Med. 2017;68:139–52.
3. Turtle CJ. Chimeric antigen receptor modified T cell therapy for B cell malignancies. Int J Hematol. 2014;99(2):132–40.
4. Kite Pharma. YESCARTA™ (axicabtagene ciloleucel) suspension for intravenous infusion. Prescribing information. Initial US approval: 2017. 2020.
5. Novartis Pharmaceuticals. KYMRIAH™ (tisagenlecleucel) suspension for intravenous infusion—US Label. Highlights of and full prescribing information. East Hanover, NJ. Initial US approval: 2017. 2018.
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献